arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

NEOGEN CORP

NEOG
$11.68 ▼ -0.78 (-6.26%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

NEOGEN CORP faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.5B
Dividend Yield —
Revenue Growth -2.7% ↗
Op. Margin -2.5% ↗
ROIC -0.7% ↗
FCF / Share $0.38 ↗
Trailing P/E —
Price / Book 1.2x
FCF Yield 3.3%
Debt / Equity 0.38
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$870.40M
↓ -2.7% —
Net Income Profit after all expenses
$-7.90M
↑ +99.3% —
Operating Margin Operating profit as % of sales
-2.5%
↑ +97.9% 20th
FCF / Share Free cash flow per share
$0.38
↑ +42.6% —
Long-Term Debt Long-term obligations
$793.70M
↓ -9.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
35
Returns
41
Financial Health ↑
48
Cash Quality
3

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 67 quarters